Literature DB >> 25921687

ALDH1 Expression and the Prognosis of Lung Cancer: A Systematic Review and Meta-Analysis.

Dong Wei1, Jing-Jing Peng1, Hui Gao1, Tao Zhang1, Yong Tan1, Yong-He Hu2.   

Abstract

PURPOSE: Aldehyde dehydrogenase 1 (ALDH1) has been identified as a putative cancer stem cell (CSC) marker in lung cancer. However, the clinicopathological and prognostic value of this protein in lung cancer patients remains controversial. Thus, we performed a systematic review and meta-analysis of studies assessing the clinical and prognostic significance of ALDH1 expression in lung cancer.
METHODS: An identification and review of publications assessing clinical or prognostic significance of ALDH1 expression in lung cancer until September 1, 2014 was undertaken. A meta-analysis was performed to clarify the association between ALDH1 expression and clinical outcomes.
RESULTS: A total of 14 publications met the criteria and comprised 1926 cases. Analysis of these data showed that ALDH1 expression was not significantly associated with the patient age (OR = 0.82, 95% confidence interval [CI]: 0.45-1.50, P=0.52), tumour size (OR=0.68, 95% CI: 0.22-2.06, P=0.49), smoking status (OR=1.37, 95% CI: 0.85-2.22, P=0.19), or tumour grade (OR=1.65, 95% CI: 0.83-3.26, P=0.15). However, in the identified studies, ALDH1 expression was highly correlated with lymph node metastasis (OR=1.97, 95% CI: 1.16-3.34, P=0.01), tumour TNM staging (OR=1.68, 95% CI 1.28-2.22, P=0.0002), decreased overall survival (relative risk [RR]: 1.97,95% CI: 1.16-3.34, P =0.01) and decreased disease free survival (RR: 1.63, 95% CI: 1.01-2.64, P=0.05).
CONCLUSIONS: This meta-analysis shows ALDH1 expression in lung cancer is connected with decreased overall and disease free survival and thus marks a worse prognosis.
Copyright © 2015. Published by Elsevier B.V.

Entities:  

Keywords:  Cancer stem cell; Disease-free survival; Meta-analysis; Overall survival; Prognosis

Mesh:

Substances:

Year:  2015        PMID: 25921687     DOI: 10.1016/j.hlc.2015.03.021

Source DB:  PubMed          Journal:  Heart Lung Circ        ISSN: 1443-9506            Impact factor:   2.975


  18 in total

Review 1.  The immunomodulatory role of all-trans retinoic acid in tumor microenvironment.

Authors:  Guoshu Bi; Jiaqi Liang; Yunyi Bian; Guangyao Shan; Valeria Besskaya; Qun Wang; Cheng Zhan
Journal:  Clin Exp Med       Date:  2022-07-13       Impact factor: 5.057

2.  IL22 Promotes Kras-Mutant Lung Cancer by Induction of a Protumor Immune Response and Protection of Stemness Properties.

Authors:  Nasim Khosravi; Mauricio S Caetano; Amber M Cumpian; Nese Unver; Cynthia De la Garza Ramos; Oscar Noble; Soudabeh Daliri; Belinda J Hernandez; Berenice A Gutierrez; Scott E Evans; Samir Hanash; Andrei M Alekseev; Yi Yang; Seon Hee Chang; Roza Nurieva; Humam Kadara; Jichao Chen; Edwin J Ostrin; Seyed Javad Moghaddam
Journal:  Cancer Immunol Res       Date:  2018-05-15       Impact factor: 11.151

3.  The SOX9-Aldehyde Dehydrogenase Axis Determines Resistance to Chemotherapy in Non-Small-Cell Lung Cancer.

Authors:  Maria A Voronkova; Liying W Rojanasakul; Chayanin Kiratipaiboon; Yon Rojanasakul
Journal:  Mol Cell Biol       Date:  2020-01-03       Impact factor: 4.272

4.  Tumor-Derived Retinoic Acid Regulates Intratumoral Monocyte Differentiation to Promote Immune Suppression.

Authors:  Samir Devalaraja; Tsun Ki Jerrick To; Ian W Folkert; Ramakrishnan Natesan; Md Zahidul Alam; Minghong Li; Yuma Tada; Konstantin Budagyan; Mai T Dang; Li Zhai; Graham P Lobel; Gabrielle E Ciotti; T S Karin Eisinger-Mathason; Irfan A Asangani; Kristy Weber; M Celeste Simon; Malay Haldar
Journal:  Cell       Date:  2020-03-12       Impact factor: 66.850

5.  The prognostic roles of ALDH1 isoenzymes in gastric cancer.

Authors:  Kai Li; Xiaoguang Guo; Ziwei Wang; Xiaofeng Li; Youquan Bu; Xuefeng Bai; Liansheng Zheng; Ying Huang
Journal:  Onco Targets Ther       Date:  2016-06-07       Impact factor: 4.147

Review 6.  Aldehyde dehydrogenase 1A1 in stem cells and cancer.

Authors:  Hiroyuki Tomita; Kaori Tanaka; Takuji Tanaka; Akira Hara
Journal:  Oncotarget       Date:  2016-03-08

7.  Clinicopathological characteristics and prognostic value of cancer stem cell marker CD133 in breast cancer: a meta-analysis.

Authors:  Zhan Li; Songcheng Yin; Lei Zhang; Weiguang Liu; Bo Chen; Hua Xing
Journal:  Onco Targets Ther       Date:  2017-02-14       Impact factor: 4.147

8.  Identification of feature risk pathways of smoking-induced lung cancer based on SVM.

Authors:  Rongjun Chen; Jinhui Lin
Journal:  PLoS One       Date:  2020-06-04       Impact factor: 3.240

9.  Dual disruption of aldehyde dehydrogenases 1 and 3 promotes functional changes in the glutathione redox system and enhances chemosensitivity in nonsmall cell lung cancer.

Authors:  Rocio Rebollido-Rios; Geoffroy Venton; Sara Sánchez-Redondo; Carmela Iglesias I Felip; Guy Fournet; Elena González; Wilber Romero Fernández; Dasiel Oscar Borroto Escuela; Barbara Di Stefano; Reinier Penarroche-Díaz; Guillaume Martin; Ismail Ceylan; Regis Costello; Mileidys Perez-Alea
Journal:  Oncogene       Date:  2020-02-03       Impact factor: 9.867

10.  Biomarkers of tumor invasiveness in proteomics (Review).

Authors:  Daniel L Pouliquen; Alice Boissard; Olivier Coqueret; Catherine Guette
Journal:  Int J Oncol       Date:  2020-05-28       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.